Andreas Grauer

机构：Omeros Corporation (United States) · ORCID：0000-0001-5098-8262

发表论文 196 篇 · 总被引 13117 次 · h-index 45

代表论文

• Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials (2020 · The Lancet Diabetes & Endocrinology · 被引 235)
• Determinants of imminent fracture risk in postmenopausal women with osteoporosis (2020 · Osteoporosis International · 被引 173)
• A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures (2020 · Journal of Bone and Joint Surgery · 被引 90)
• A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab (2020 · Osteoporosis International · 被引 49)
• Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors (2022 · Clinical Cancer Research · 被引 38)
• Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial (2019 · Journal of Bone and Mineral Metabolism · 被引 35)